Literature DB >> 9202846

Molecular mechanisms regulating the myofilament response to Ca2+: implications of mutations causal for familial hypertrophic cardiomyopathy.

K A Palmiter1, R J Solaro.   

Abstract

In this chapter we consider a current perception of the molecular mechanisms controlling myofilament activation with emphasis on alterations that may occur in familial hypertrophic cardiomyopathy (FHC). FHC is a sarcomeric disease (100) with an autosomal dominant pattern of heritability (27, 51). There is a substantial body of evidence implicating missense mutations in the beta-MHC gene as causal for the development of this disease. Recently, mutations in genes of two thin filament regulatory proteins, cardiac troponin T(cTnT) and alpha-tropomyosin (alpha-Tm), have also been linked to FHC. The commonality among the functional consequences of these mutations remains an important question. This review discusses how these pathological mutations may impact the activation process by disrupting critical structure function relations in both the thick and thin filaments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202846     DOI: 10.1007/bf00794070

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  8 in total

Review 1.  Integration of pathways that signal cardiac growth with modulation of myofilament activity.

Authors:  R John Solaro; David M Montgomery; Lynn Wang; Eileen M Burkart; Yunbo Ke; Susan Vahebi; Peter Buttrick
Journal:  J Nucl Cardiol       Date:  2002 Sep-Oct       Impact factor: 5.952

2.  A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.

Authors:  J D Molkentin; J R Lu; C L Antos; B Markham; J Richardson; J Robbins; S R Grant; E N Olson
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

3.  Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling.

Authors:  Zai Hao Zhao; Chun Li Jin; Ji Hyun Jang; Yu Na Wu; Sung Joon Kim; Hong Hua Jin; Lan Cui; Yin Hua Zhang
Journal:  J Vis Exp       Date:  2016-08-01       Impact factor: 1.355

4.  Unequal allelic expression of wild-type and mutated β-myosin in familial hypertrophic cardiomyopathy.

Authors:  Snigdha Tripathi; Imke Schultz; Edgar Becker; Judith Montag; Bianca Borchert; Antonio Francino; Francisco Navarro-Lopez; Andreas Perrot; Cemil Özcelik; Karl-Josef Osterziel; William J McKenna; Bernhard Brenner; Theresia Kraft
Journal:  Basic Res Cardiol       Date:  2011-07-19       Impact factor: 17.165

5.  SERCA2 Haploinsufficiency in a Mouse Model of Darier Disease Causes a Selective Predisposition to Heart Failure.

Authors:  Vikram Prasad; John N Lorenz; Valerie M Lasko; Michelle L Nieman; Wei Huang; Yigang Wang; David W Wieczorek; Gary E Shull
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

6.  Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy.

Authors:  Mareomi Hamada; Yuji Shigematsu; Shuntaro Ikeda; Kiyotaka Ohshima; Akiyoshi Ogimoto
Journal:  ESC Heart Fail       Date:  2021-10-29

Review 7.  The potential role of MLC phosphatase and MAPK signalling in the pathogenesis of vascular dysfunction in heart failure.

Authors:  Ozgur Ogut; Frank V Brozovich
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

Review 8.  From stem cells to cardiomyocytes: the role of forces in cardiac maturation, aging, and disease.

Authors:  Gaurav Kaushik; Adam J Engler
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.